The Simultaneous Inhibition of Solute Carrier Family 6 Member 19 and Breast Cancer Resistance Protein Transporters Leads to an Increase of Indoxyl Sulfate (a Uremic Toxin) in Plasma and Kidney.

Autor: Wang Q; Department of Drug Metabolism and Pharmacokinetics (Q.W., Y.L., J.F.), Integrated Drug Discovery (J.L.K., T.K.), and Preclinical Safety Research (E.-J.P., M.S., Z.J.), Sanofi, Cambridge, Massachusetts; Department of Drug Metabolism and Pharmacokinetics, Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany (B.M., A.M., C.H., J.R.) qingping.wang@sanofi.com., Munteanu B; Department of Drug Metabolism and Pharmacokinetics (Q.W., Y.L., J.F.), Integrated Drug Discovery (J.L.K., T.K.), and Preclinical Safety Research (E.-J.P., M.S., Z.J.), Sanofi, Cambridge, Massachusetts; Department of Drug Metabolism and Pharmacokinetics, Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany (B.M., A.M., C.H., J.R.)., Marker A; Department of Drug Metabolism and Pharmacokinetics (Q.W., Y.L., J.F.), Integrated Drug Discovery (J.L.K., T.K.), and Preclinical Safety Research (E.-J.P., M.S., Z.J.), Sanofi, Cambridge, Massachusetts; Department of Drug Metabolism and Pharmacokinetics, Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany (B.M., A.M., C.H., J.R.)., Luo Y; Department of Drug Metabolism and Pharmacokinetics (Q.W., Y.L., J.F.), Integrated Drug Discovery (J.L.K., T.K.), and Preclinical Safety Research (E.-J.P., M.S., Z.J.), Sanofi, Cambridge, Massachusetts; Department of Drug Metabolism and Pharmacokinetics, Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany (B.M., A.M., C.H., J.R.)., Holz C; Department of Drug Metabolism and Pharmacokinetics (Q.W., Y.L., J.F.), Integrated Drug Discovery (J.L.K., T.K.), and Preclinical Safety Research (E.-J.P., M.S., Z.J.), Sanofi, Cambridge, Massachusetts; Department of Drug Metabolism and Pharmacokinetics, Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany (B.M., A.M., C.H., J.R.)., Kane JL Jr; Department of Drug Metabolism and Pharmacokinetics (Q.W., Y.L., J.F.), Integrated Drug Discovery (J.L.K., T.K.), and Preclinical Safety Research (E.-J.P., M.S., Z.J.), Sanofi, Cambridge, Massachusetts; Department of Drug Metabolism and Pharmacokinetics, Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany (B.M., A.M., C.H., J.R.)., Kuntzweiler T; Department of Drug Metabolism and Pharmacokinetics (Q.W., Y.L., J.F.), Integrated Drug Discovery (J.L.K., T.K.), and Preclinical Safety Research (E.-J.P., M.S., Z.J.), Sanofi, Cambridge, Massachusetts; Department of Drug Metabolism and Pharmacokinetics, Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany (B.M., A.M., C.H., J.R.)., Poulton EJ; Department of Drug Metabolism and Pharmacokinetics (Q.W., Y.L., J.F.), Integrated Drug Discovery (J.L.K., T.K.), and Preclinical Safety Research (E.-J.P., M.S., Z.J.), Sanofi, Cambridge, Massachusetts; Department of Drug Metabolism and Pharmacokinetics, Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany (B.M., A.M., C.H., J.R.)., Sedic M; Department of Drug Metabolism and Pharmacokinetics (Q.W., Y.L., J.F.), Integrated Drug Discovery (J.L.K., T.K.), and Preclinical Safety Research (E.-J.P., M.S., Z.J.), Sanofi, Cambridge, Massachusetts; Department of Drug Metabolism and Pharmacokinetics, Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany (B.M., A.M., C.H., J.R.)., Jayyosi Z; Department of Drug Metabolism and Pharmacokinetics (Q.W., Y.L., J.F.), Integrated Drug Discovery (J.L.K., T.K.), and Preclinical Safety Research (E.-J.P., M.S., Z.J.), Sanofi, Cambridge, Massachusetts; Department of Drug Metabolism and Pharmacokinetics, Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany (B.M., A.M., C.H., J.R.)., Riedel J; Department of Drug Metabolism and Pharmacokinetics (Q.W., Y.L., J.F.), Integrated Drug Discovery (J.L.K., T.K.), and Preclinical Safety Research (E.-J.P., M.S., Z.J.), Sanofi, Cambridge, Massachusetts; Department of Drug Metabolism and Pharmacokinetics, Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany (B.M., A.M., C.H., J.R.)., Fretland J; Department of Drug Metabolism and Pharmacokinetics (Q.W., Y.L., J.F.), Integrated Drug Discovery (J.L.K., T.K.), and Preclinical Safety Research (E.-J.P., M.S., Z.J.), Sanofi, Cambridge, Massachusetts; Department of Drug Metabolism and Pharmacokinetics, Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany (B.M., A.M., C.H., J.R.).

Publikováno v: Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2024 Oct 16; Vol. 52 (11), pp. 1288-1296. Date of Electronic Publication: 2024 Oct 16.

A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells.

Autor: Seung E; Sanofi R&D, North America, Cambridge, MA, USA.; ModeX Therapeutics, Natick, MA, USA., Xing Z; Sanofi R&D, North America, Cambridge, MA, USA., Wu L; Sanofi R&D, North America, Cambridge, MA, USA.; ModeX Therapeutics, Natick, MA, USA., Rao E; Sanofi R&D, Frankfurt, Frankfurt am Main, Germany., Cortez-Retamozo V; Sanofi R&D, North America, Cambridge, MA, USA., Ospina B; Sanofi R&D, North America, Cambridge, MA, USA., Chen L; Sanofi R&D, North America, Cambridge, MA, USA., Beil C; Sanofi R&D, Frankfurt, Frankfurt am Main, Germany., Song Z; Sanofi R&D, North America, Cambridge, MA, USA., Zhang B; Sanofi R&D, North America, Cambridge, MA, USA., Levit M; Sanofi R&D, North America, Cambridge, MA, USA., Deng G; Sanofi R&D, North America, Cambridge, MA, USA., Hebert A; Sanofi R&D, North America, Cambridge, MA, USA., Kirby P; Sanofi R&D, North America, Cambridge, MA, USA.; Dragonfly Therapeutics, Waltham, MA, USA., Li A; Sanofi R&D, North America, Cambridge, MA, USA., Poulton EJ; Sanofi R&D, North America, Cambridge, MA, USA., Vicente R; Sanofi R&D, Montpellier, Montpellier, France., Garrigou A; Sanofi R&D, Montpellier, Montpellier, France., Piepenhagen P; Sanofi R&D, North America, Cambridge, MA, USA., Ulinski G; Sanofi R&D, North America, Cambridge, MA, USA., Sanicola-Nadel M; Sanofi R&D, North America, Cambridge, MA, USA.; GSK, Waltham, MA, USA., Bangari DS; Sanofi R&D, North America, Cambridge, MA, USA., Qiu H; Sanofi R&D, North America, Cambridge, MA, USA., Pao L; Sanofi R&D, North America, Cambridge, MA, USA. Lily.Pao@sanofi.com., Wiederschain D; Sanofi R&D, North America, Cambridge, MA, USA.; Jounce Therapeutics, Cambridge, MA, USA., Wei R; Sanofi R&D, North America, Cambridge, MA, USA.; ModeX Therapeutics, Natick, MA, USA., Yang ZY; Sanofi R&D, North America, Cambridge, MA, USA. Zhi-yong.Yang@modextx.com.; ModeX Therapeutics, Natick, MA, USA. Zhi-yong.Yang@modextx.com., Nabel GJ; Sanofi R&D, North America, Cambridge, MA, USA. Gary.Nabel@modextx.com.; ModeX Therapeutics, Natick, MA, USA. Gary.Nabel@modextx.com.

Publikováno v: Nature [Nature] 2022 Mar; Vol. 603 (7900), pp. 328-334. Date of Electronic Publication: 2022 Feb 23.

Enhancement of hepatic 4-hydroxylation of 25-hydroxyvitamin D3 through CYP3A4 induction in vitro and in vivo: implications for drug-induced osteomalacia.

Autor: Wang Z; Department of Pharmaceutics, University of Washington, Seattle, WA 98195-7610, USA., Lin YS, Dickmann LJ, Poulton EJ, Eaton DL, Lampe JW, Shen DD, Davis CL, Shuhart MC, Thummel KE

Publikováno v: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research [J Bone Miner Res] 2013 May; Vol. 28 (5), pp. 1101-16.

The dietary isothiocyanate sulforaphane is an antagonist of the human steroid and xenobiotic nuclear receptor.

Autor: Zhou C; Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, WA 98195, USA., Poulton EJ, Grün F, Bammler TK, Blumberg B, Thummel KE, Eaton DL

Publikováno v: Molecular pharmacology [Mol Pharmacol] 2007 Jan; Vol. 71 (1), pp. 220-9. Date of Electronic Publication: 2006 Oct 06.